Michael Chorev

Brigham and Women's Hospital — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

48h-index8.3kcitations239works1.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chemical Synthesis and Analysis(95), Bone health and treatments(40), Receptor Mechanisms and Signaling(29), Neuropeptides and Animal Physiology(26), Click Chemistry and Applications(22)

Publications239 total

Activity of the Di-Substituted Urea-Derived Compound I-17 in Leishmania In Vitro Infections
Pathogens·2024· 1 citedOpen Access
Activity of the Di-Substituted Urea-Derived Compound I-17 in Leishmania Infections
Preprints.org·2023· 1 citedOpen Access
Parathyroid hormone receptors in GtoPdb v.2023.1
IUPHAR/BPS Guide to Pharmacology CITE·2023· 1 citedOpen Access
Supplementary Figure 1 from Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
2023Open Access
Supplementary Figure 3 from Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
2023Open Access
Supplementary Figure Legends 1-5 from Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
2023Open Access
Supplementary Materials and Methods from Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
2023Open Access
Supplementary Figure 2 from Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
2023Open Access
Supplementary Figure 2 from Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
2023Open Access
Supplementary Figure 5 from Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
2023Open Access
Supplementary Figure 1 from Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
2023Open Access
Supplementary Materials and Methods from Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
2023Open Access
Supplementary Figure 3 from Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
2023Open Access
Supplementary Figure Legends 1-5 from Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
2023Open Access
Supplementary Figure 4 from Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
2023Open Access
Data from Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
2023Open Access
Data from Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
2023Open Access
Supplementary Figure 4 from Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
2023Open Access
Supplementary Figure 5 from Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
2023Open Access
Role of symmetry in 3,3-diphenyl-1,3-dihydroindol-2-one derivatives as inhibitors of translation initiation
Bioorganic & Medicinal Chemistry Letters·2022· 1 citedOpen Access
page 1 of 12Next →

Frequent Co-authors

Michael Rosenblatt(17), José A. Halperin(13), Alessandro Bisello(11), Dale F. Mierke(7), Jay J. Levy(6), Gerhard Wagner(5), Chaim Gilon(5), Larry J. Suva(5), Itai Bab(5), Bertal H. Aktas(5), Mark E. Goldman(5), Murray Goodman(4), Rupam Sahoo(4), Vered Behar(4), Roberta L. McKee(4), Hüseyin Aktaş(3), Sonia Cantel(3), Maria Pellegrini(3), Allison B. Goldfine(3), Pamela Ghosh(3)